Global Invasive Fungal Infection Market Size Study & Forecast, by Disease Type (Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others), By Drug Type (Polye

Global Invasive Fungal Infection Market Size Study & Forecast, by Disease Type (Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others), By Drug Type (Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, Others), and Regional Analysis, 2023-2030

Global Invasive Fungal Infection Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. An invasive fungal infection is a serious infection that occurs when fungi enter the bloodstream and spread to other parts of the body. These infections can be life-threatening, especially in people who are immunocompromised, such as those with cancer, HIV/AIDS, or organ transplants. There are many different types of fungi that cause invasive fungal infections. The Invasive Fungal Infection Market is expanding because of factors such as the growing initiatives by public and private organizations to raise awareness about a variety of fungal infections, rising disposable income of people, and increasing incidence of invasive fungal infections.

In addition, the rise in the population suffering from HIV is acting as a catalyzing factor for market growth across the globe. ``According to HIV.gov, in 2021, it was estimated that nearly 38.4 million people worldwide are suffering from HIV, of which 1.7 million were children (<15 years old) and 36.7 million were adults. Also, in 2021, approximately 1.5 million individuals around the globe acquired HIV. Thus, these aforementioned factors are propelling the growth of the Invasive Fungal Infection Market during the estimated period. Moreover, the discoveries and advancements of pipeline drugs and facilities, as well as the growing demand for novel antifungal drugs present various lucrative opportunities over the forecasting years. However, the unavailability of skilled professionals and the lack of awareness are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Invasive Fungal Infection Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the prolonged hospital stays, rising use of immunosuppressive therapies, and fungal colonization or infection at other sites. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The rise in the population suffering from HIV, rising disposable income, and raise awareness about a variety of fungal infections are significantly propelling the market demand across the region.

Major market players included in this report are:
Cidara Therapeutics, Inc.
Basilea Pharmaceutica AG Allschwil
Pfizer
GlaxoSmith Kline
Bayer AG
Abbott
Merck & Co, Inc.
Astellas Pharma Inc.
Scynexis Inc.
BioMarin Pharmaceutical Inc.

Recent Developments in the Market:
In March 2023, the U.S. Food and Drug Administration (FDA) has granted approval for rezafungin for injection, (REZZAYOTM), as a treatment for patients with candidemia and invasive candidiasis. The newly approved drug is the first to be licenced in more than ten years for the invasive fungal disease. It is a new antifungal treatment administered intravenously once a week.

Global Invasive Fungal Infection Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Disease Type, Drug Type, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Disease Type:
Candidaemi Caa and Invasive Candiasis
Intra-abdominal Candiasis
Cryptococcal Meningitis
Esophageal Candidiasis
Histoplasmosis Acute Pulmonary
Others

By Drug Type:
Polyenes
Amphotericin B Deoxycholate
Lipid Formulation Amphotericin B
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa


Companies
Cidara Therapeutics, Inc.
Basilea Pharmaceutica AG Allschwil
Pfizer
GlaxoSmith Kline
Bayer AG
Abbott
Merck & Co, Inc.
Astellas Pharma Inc.
Scynexis Inc.
BioMarin Pharmaceutical Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.